Routine Versus Selective Use of FFR to Guide PCI

Acute Coronary Syndrome Clinical Trial

— FFR-SELECT  

Official title:

A Randomized Comparative Effectiveness Study of Routine Versus Selective Use of Fractional Flow Reserve (FFR) to Guide Non-Emergent Percutaneous Coronary Intervention (PCI)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02000661
• Other study ID #: H13-02709
• Status: Terminated
• Phase: Phase 4
• Start date: January 2014
• Est. completion date: February 2017

Study information

• Verified date: February 2019
• Source: Cardiology Research UBC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Fractional flow reserve (FFR) is a test that can be performed at the time of heart catheterization. It measures the change in pressure across a narrowing in the heart artery during high flow situation, and provides reliable information about the functional severity of the narrowing. FFR measurements accurately predict whether a stent is needed, and is considered an excellent test before placement of stents to treat narrowed heart arteries. However, FFR is not used in every case because of the extra time needed and the associated device costs. Cardiac Services BC (an agency of Provincial Health Services Authority) is sponsoring this study to find out if FFR should be used in most cases (routine), rather than the current selective approach.

Description:

Percutaneous coronary intervention (PCI) is an effective, less invasive mode of revascularization compared with coronary artery bypass grafting (CABG). In 2011, a total of 7,614 PCI procedures were performed in British Columbia (BC). While some procedures were done emergently for life-threatening indications (e.g. ST elevation myocardial infarction - STEMI or cardiogenic shock), most (6,169 cases in year 2011) were done at the discretion of the treating physicians, taking patient preference into account. A number of factors are usually considered before proceeding with PCI. These may include clinical presentation (stable angina versus acute coronary syndrome); severity of symptoms (asymptomatic or highly symptomatic); response to medical therapy; severity of ischemia based on non-invasive functional testing (mild, moderate, or severe); predicted risk (low, intermediate, or high); and findings on coronary angiography (lesion number, location, severity, and morphology, etc). However, interpretation of symptoms is subjective. Non-invasive tests for ischemia may not be reliable. In addition, coronary angiography uses 2 dimensional images to depict 3-dimensional structures, and there is well known limitations.

The concept of using fractional flow reserve (FFR) to predict the functional significance of coronary lesions was described > 20 years ago. In 1996, Pijls et al showed that measurements of FFR in the cardiac catheterization laboratory can accurately predict provoked ischemia upon non-invasive functional testing. The DEFER study (2007) showed that coronary lesions with non-ischemic FFR values can be treated with medical therapy with good clinical outcome at 5-year follow up. The FAME-1 study (2009) evaluated the strategy of PCI guided by angiography versus PCI guided by FFR measurements in multi-vessel disease. The primary end-point was the 1-year composite of death, myocardial infarction (MI), and any repeat revascularization. Fewer stents were used per patient for the FFR-guided group (2.7 versus 1.9 stents per patient), less contrast agent used (302 versus 272 ml), and lower in-lab equipment cost ($6,007 US versus $5,332 US), all significant with P<0.001. A total of 1,005 patients were randomized. At 1-year follow up, the composite end-point of death, MI and target vessel revascularization was 18.2% for the angiography-guided group versus 13.3% for the FFR-guided group (p < 0.02). At 2-year follow up, the incidence of death and MI was lower for the FFR-guided group (12.7% versus 8.4%, p<0.03), and the incidence of MI in the FFR-guided and PCI deferred population was very low at 0.2%.

Since the publication of the FAME-1 study, the use of pressure wires to measure FFR increased from ~400 cases per year to ~1,000 cases per year in BC. However, in comparison with an annual non-emergent PCI volume of >6,000 cases per year, the use of FFR appears highly selective (1,058 out of 6,169, 17%, based on year 2011 statistics). In a series of 442 consecutive FFR cases done at the Vancouver General and St. Paul's Hospitals (year 2011 to 2012), the use of FFR identified non-ischemic lesions in 52%, and this resulted in a change in management decision in 68%. In addition, provincial data showed significant variation in the use of FFR among the 5 PCI capable hospitals in BC (from <5% to ~30%). Based on the recent European Society of Cardiology guidelines, the use of FFR to guide revascularization has a class 1a indication in multi-vessel disease, while the US guidelines (American College of Cardiology, ACC) has a class 2a recommendation for the use of FFR in evaluating coronary lesions of intermediate severity. It is possible that a highly selective approach to the use of FFR may lead to underuse, which in turn may lead to overuse of PCI, with increased cost, and adverse clinical outcome.

We hypothesize that the routine use of FFR may improve clinical outcome, decrease the number of PCI, and decrease direct cost in the cardiac catheterization laboratory. We propose a randomized study to compare 2 approaches of using FFR to guide PCI: (1) routine use - the experimental arm; and (2) selective use - the current standard.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 261
• Est. completion date: February 2017
• Est. primary completion date: February 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects with stable coronary artery disease or recent acute coronary syndrome (ACS). Subjects who present with ST elevation myocardial infarction (STEMI) are allowed to be included after 5 days from initial presentation.

2. At least one obstructive coronary lesion is present with vessel reference diameter =2.5 mm and diameter stenosis =50% by visual estimate. Lesions must be technically suitable for the FFR procedure and angioplasty with stent placement.

3. Physician will classify all target lesions and need for FFR before randomization, and there is a plan to perform a non-emergent PCI.

4. Subject is =18 years old, with signed informed consent.

Exclusion Criteria:

1. Expected non-cardiac longevity < 2 years.

2. Planned treatment with CABG.

3. Planned treatment with medical therapy.

4. Left main disease > 50% diameter stenosis based on visual estimate.

5. Safety issues:

1. Unstable hemodynamics or serious arrhythmias during procedure;

2. Ongoing ischemic chest pain;

3. High grade AV block (unless pacemaker);

4. Allergic to adenosine.

6. When FFR is clearly not needed:

1. Target vessel with slow flow (< TIMI-3);

2. Single vessel disease with =90% stenosis;

3. Single vessel disease with =80% stenosis and documented ischemia on functional imaging test;

4. In acute coronary syndrome, =70 stenosis identified as culprit.

7. When FFR is clearly needed for all target lesions: as declared by the operator.

8. Technical difficulty:

1. Severe vessel tortuosity;

2. Severe coronary calcification;

3. Anticipate difficult wiring;

4. Aorto-ostial lesion (ok for IV adenosine is used as the hyperemic agent).

9. Interpretation difficulty:

1. Target vessel acting as a major collateral donor;

2. When RA pressure very high;

3. STEMI within past 5 days.

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Angina, Unstable
• Atherosclerosis
• Coronary Artery Disease
• Coronary Atherosclerosis
• Myocardial Ischemia

Intervention

Device:
• Fractional Flow Reserve (FFR)
Fractional Flow Reserve (FFR) performed per guidelines to guide PCI

Locations

Country	Name	City	State
Canada	Kelowna General Hospital	Kelowna	British Columbia
Canada	St. Paul's Hospital	Vancouver	British Columbia
Canada	Vancouver General Hospital	Vancouver	British Columbia
Canada	Royal Jubilee Hospital	Victoria	British Columbia

Sponsors (2)

Lead Sponsor	Collaborator
Cardiology Research UBC	Provincial Health Services Authority

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Economic evaluation, including health resource utilization		1 Year
Primary	Composite of all cause mortality, repeat hospitalization for MI or repeat revascularization (PCI or coronary artery bypass grafting - CABG)		1 Year
Secondary	All cause mortality		1 Year
Secondary	Repeat hospitalization for MI		1 Year
Secondary	Rate of repeat revascularization (PCI or CABG)		1 Year
Secondary	Time of procedure, contrast amount, and radiation dose		Post-procedure